Quarterly report · Q3
4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥683.0bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥239.1bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥618.0bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥214.7bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥105.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥39.0bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥93.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥105.7bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥39.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥92.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥1.69T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.54T | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥475.7bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.22T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.22T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.07T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥163.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥162.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥91.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥53.1bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥41.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥68.7bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥84.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥107.33 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥40.06 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥93.25 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥107.29 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥40.05 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.21 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥39.96 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.9% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.6% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-12-31 | ¥172m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥2.1bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥127.8bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥13.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥407.7bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥92.0bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥147.3bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥16.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥682.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥121.9bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-12-31 | ¥186m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥479m |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥113.4bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥358.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥83.6bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥145.5bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥617.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥109.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 653
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -29618000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -9464000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | 1911000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -7875000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -8769000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 1554000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 99164000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 128237000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 1756000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 2274000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -1222000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -1120000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -24832000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -38190000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 74866000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 91200000000 | JPY |
| Payments into time deposits inv cf IFRS | Prior1YTDDuration | -178000000 | JPY |
| Payments into time deposits inv cf IFRS | CurrentYTDDuration | -799000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf IFRS | Prior1YTDDuration | 1000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf IFRS | CurrentYTDDuration | 4000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -37964000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -40421000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1YTDDuration | 453000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | CurrentYTDDuration | 718000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -14689000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -13439000000 | JPY |
| Purchase of marketable securities inv cf IFRS | Prior1YTDDuration | -1238000000 | JPY |
| Purchase of marketable securities inv cf IFRS | CurrentYTDDuration | -2356000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | Prior1YTDDuration | 3527000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | CurrentYTDDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -143000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -124000000 | JPY |
| Proceeds from sales of shares of subsidiaries and affiliates inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sales of shares of subsidiaries and affiliates inv cf IFRS | CurrentYTDDuration | 2921000000 | JPY |
| Proceeds from sale of businesses and other inv cf IFRS | Prior1YTDDuration | 8325000000 | JPY |
| Proceeds from sale of businesses and other inv cf IFRS | CurrentYTDDuration | 429000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -41905000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -53065000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1YTDDuration | 682000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1YTDDuration | -682000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -938000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -985000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1YTDDuration | － | JPY |
| Redemption of bonds fin cf IFRS | CurrentYTDDuration | -10000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -5562000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -5719000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -50084000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -7950000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |